Lanean...
Cell Therapy for Stroke: Remaining Issues to Address Before Embarking on Clinical Trials
BACKGROUND AND PURPOSE: Stroke remains a significant clinical unmet condition, with only 3% of ischemic patient population benefiting from the thrombolytic drug tissue plasminogen activator largely because of the drug's narrow 3-hour therapeutic window. Extending the stroke therapeutic window w...
Gorde:
| Argitaratua izan da: | Stroke |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2008
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4810678/ https://ncbi.nlm.nih.gov/pubmed/19064801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.108.533091 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|